CLEC2A CAR T for AML

(ADVANCE-01 Trial)

This trial explores a new treatment for individuals with acute myeloid leukemia (AML) that hasn't responded to treatment or has returned. It uses a type of immune cell from the patient's own blood, specially modified to better target and fight their cancer. This treatment, called SC-CAR.CLEC2Av1, is a form of CAR T-cell therapy. The main goals are to determine the treatment's safety and production feasibility. Suitable candidates for this trial include those with AML that has not improved with standard treatments or has recurred, and who can undergo a blood collection process called apheresis.

As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

Research has shown that CLEC2A CAR T cell treatments are safe for people with acute myeloid leukemia (AML). Studies found that patients did not experience major side effects unrelated to blood cells. This finding is encouraging, indicating that the treatment is generally well-tolerated. Additionally, the treatment effectively targets cancer cells without seriously harming normal cells. This evidence suggests that CLEC2A CAR T therapy is safe and potentially effective for patients with AML.¹²³⁴⁵

Most treatments for acute myeloid leukemia (AML) involve chemotherapy or stem cell transplantation. But SC-CAR.CLEC2Av1 works differently, targeting the CLEC2A antigen on cancer cells. This approach is unique because it uses genetically modified T cells, known as CAR T cells, to seek out and destroy specific cancer cells, potentially offering a more targeted and effective treatment. Researchers are excited because this could mean fewer side effects compared to traditional chemotherapy and a powerful new way to attack cancer at its core.

Research has shown that CAR T cell therapies hold promise for treating acute leukemias, with complete remission rates between 70% and 90%. One specific CAR T cell therapy targeting a similar marker (CLEC12A) demonstrated an overall response rate of 82.5%. In this trial, the SC-CAR.CLEC2Av1 treatment aims to attack and eliminate AML cancer cells without harming normal blood cells, a common issue with other treatments. Although specific data on SC-CAR.CLEC2Av1 remains limited, findings from related studies suggest it could effectively treat hard-to-treat or recurrent acute myeloid leukemia (AML).⁶⁷⁸⁹¹⁰